Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 11 - 27

Xunlu Bio's Fucaso® Approved by Hong Kong for Relapsed/Refractory Multiple Myeloma

On November 27, 2025, Xunlu Bio announced that its independently developed fully human BCMA-targeted CAR-T cell therapy product Fucaso® (Equecabtagene Autoleucel) has received approval from the Hong Kong Department of Health for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least three prior lines of therapy.This marks Fucaso® as the first China-developed CAR-T cell therapy product approved in Hong Kong, and also the first domestically produced ATMP (Advanced Therapy Medicinal Product) to receive international PIC/S...

浏览次数：1

查看详情>>

发布时间: 2025 - 11 - 24

Jingwei Shida Secures Over RMB 100 Million to Advance Global Precision Diagnosis

Recently, Jingwei Shida Medical Technology Co., Ltd. ("Jingwei Shida") announced the completion of a new financing round exceeding RMB 100 million, co-led by Efung Zhuohua Fund, Huabin Fengtai Private Equity Fund, and Changfei Industrial Fund. The funds will be primarily used for continued R&D, scaled production, clinical application promotion, and global commercialization of confocal microscopy endoscopy products.As a high-end medical device enterprise focused on precision diagnosis and treatment of early-stage tumors, Jingwei Shida has remained committed to its vision and missi...

浏览次数：2

查看详情>>

发布时间: 2025 - 11 - 19

People's Daily | The 20th China Economic Forum Opens in Nansha!

On November 18, the 20th China Economic Forum, hosted by China Economic Weekly magazine under People's Daily, was successfully held at the Guangzhou Nansha International Convention Center.The China Economic Forum is a major economic forum event hosted by China Economic Weekly magazine under People's Daily. Since its inception in 2001, it has had a broad influence across government, business, and academic circles.It is reported that the theme of this year's forum is "Chinese Modernization and the Outlook for China's Economy in the 15th Five-Year Plan.&qu...

浏览次数：2

查看详情>>

发布时间: 2025 - 11 - 12

Andao Pharma Announces Completion of Over RMB 400 Million Series C Financing

Recently, Hangzhou Andao Pharmaceutical Co., Ltd. announced the completion of a Series C financing round exceeding RMB 400 million. This round was invested in by Grand Pharma (with Huadong Medicine as a major LP), Taiping Medical Health Fund, C&D Emerging Investment, Hangzhou Taikun, Zhejiang Province "4+1" Biopharmaceutical and High-End Medical Device Industry Fund, Guangzhou Industrial Investment, Guangzhou Development District, Science and Technology Financial Holding, and Hangzhou Talent Fund, among others, with follow-on investments from existing shareholders including Efung...

浏览次数：1

查看详情>>